



image

\$ 1635

Applicant's Docket No. MPI00-459P1RM (previously 10147-56U1)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rachel E. Meyers, et al.
Application No.: 10/001,851 Group No.: 1635
Filed: November 20, 2001 Examiner: James Schultz
For: 47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES
THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Transmittal which includes a request for extension of time (3 pages) (in duplicate);
 - b. Response to Restriction Requirement (2 pages);
 - c. Preliminary Amendment under CFR § 1.115 (5 pages);
 - d. Transmittal of Information Disclosure Statement (2 pages);
 - e. Supplemental Information Disclosure Statement (2 pages);
 - f. Form PTO/SB/08A (1 page);
 - g. Copy of Reference cited in Information Disclosure Statement (Citation No. AA); and
 - h. Return postcard.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail.



as "Express Mail Post Office to Address"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Sean Hunziker
Signature
Sean Hunziker

(type or print name of person certifying)

Date: November 14, 2003

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 3)

11/20/2003 HGBREH1 00000025 501668 10001851

01 FC:1251 110.00 DA



Practitioner's Docket N . 10147-56U1 (previously 10147-56U1)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rachel E. Meyers, et al.
Application No.: 10/001,851
Filed: November 20, 2001
For: 47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES THEREOF

Group No.: 1635
Examiner: James Schultz

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements;
2. ☒ Forms PTO/SB/08A (substitute for Form PTO-1449);
3. ☒ Copy of Listed Information Item Accompanying This Statement (AA)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail.


☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: November 14, 2003

Signature


Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Copies of Listed Information Items Accompanying This Statement

Legible copy of item listed in Form PTO/SB/08A (substitute for Form PTO-1449) accompanies this information statement.

November 14, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Jean M. Silveri

Registration No. 39,030

75 Sidey Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820